Biotech News

Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties

Eagle Pharmaceuticals (EGRX)Eagle Pharmaceuticals2026-06-25 13:46 ESTCompany update

WOODCLIFF LAKE, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has entered into a royalty purchase agreement with an entity that was provided capital by funds managed by Blue Owl Capital Inc.

Open original release

Related news

EGRXEagle Pharmaceuticals2026-06-25 13:46 EST

Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan

EGRXEagle Pharmaceuticals2026-06-25 13:46 EST

Eagle Pharmaceuticals Announces 2025 Annual Meeting Date

EGRXEagle Pharmaceuticals2026-06-25 13:46 EST

Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors

EGRXEagle Pharmaceuticals2026-06-25 13:46 EST

Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years

EGRXEagle Pharmaceuticals2026-06-25 13:46 EST

Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements

EGRXEagle Pharmaceuticals2026-06-25 13:46 EST

Eagle Pharmaceuticals Announces Availability of Unaudited Second Quarter 2025 Financial Statements

EGRXEagle Pharmaceuticals2026-06-25 13:46 EST

Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders

EGRXEagle Pharmaceuticals2026-06-25 13:46 EST

Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan

EGRXEagle Pharmaceuticals2026-06-25 13:46 EST

Eagle Pharmaceuticals Announces Divestiture of Barhemsys

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

View all latest news

Eagle Pharmaceuticals

Eagle Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

EGRXEagle Pharmaceuticals2026-06-26 09:30 EST

Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan

EGRXEagle Pharmaceuticals2026-06-26 09:30 EST

Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties

EGRXEagle Pharmaceuticals2026-06-26 09:30 EST

Eagle Pharmaceuticals Announces 2025 Annual Meeting Date

EGRXEagle Pharmaceuticals2026-06-26 09:30 EST

Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors

EGRXEagle Pharmaceuticals2026-06-26 09:30 EST

Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States